VILLA, MATTEO
VILLA, MATTEO
DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)
Author Correction: Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer (npj Precision Oncology, (2025), 9, 1, (291), 10.1038/s41698-025-01088-0)
2025 Crippa, V; Cordani, N; Villa, A; Malighetti, F; Villa, M; Sala, L; Aroldi, A; Piazza, R; Cortinovis, D; Mologni, L; Ramazzotti, D
Comprehensive analysis of mutational processes across 20 000 adult and pediatric tumors
2025 Villa, M; Malighetti, F; De, S; Villa, A; Cordani, N; Aroldi, A; Antoniotti, M; Caravagna, G; Graudenzi, A; Piazza, R; Mologni, L; Ramazzotti, D
Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer
2025 Crippa, V; Cordani, N; Villa, A; Malighetti, F; Villa, M; Sala, L; Aroldi, A; Piazza, R; Cortinovis, D; Mologni, L; Ramazzotti, D
Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkers
2025 Villa, M; Cazzaniga, G; Bolognesi, M; Malighetti, F; Crippa, V; Aroldi, A; Bozzini, G; Pagni, F; Piazza, R; Mologni, L; Ramazzotti, D
Investigation of drug resistance and co-mutational landscape of ALK-positive tumors
2025 Villa, M
Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis
2025 Malighetti, F; Villa, M; Villa, A; Pelucchi, S; Aroldi, A; Cortinovis, D; Canova, S; Capici, S; Cazzaniga, M; Mologni, L; Ramazzotti, D; Cordani, N
Abstract 987: Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy
2024 Malighetti, F; Villa, M; Sala, E; Geeta, G; Arosio, G; Gemelli, M; Manfroni, C; Fontana, D; Cordani, N; Meneveri, R; Zambon, A; Piazza, R; Pagni, F; Cortinovis, D; Mologni, L
Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies
2024 Malighetti, F; Villa, M; Mauri, M; Piane, S; Crippa, V; Crespiatico, I; Cocito, F; Bossi, E; Steidl, C; Civettini, I; Scollo, C; Ramazzotti, D; Gambacorti-Passerini, C; Piazza, R; Mologni, L; Aroldi, A
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients
2024 Villa, M; Malighetti, F; Sala, E; Sharma, G; Arosio, G; Gemelli, M; Manfroni, C; Fontana, D; Cordani, N; Meneveri, R; Zambon, A; Piazza, R; Pagni, F; Cortinovis, D; Mologni, L
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma
2024 Villa, M; Geeta, G; Malighetti, F; Mauri, M; Arosio, G; Cordani, N; Lobello, C; Larose, H; Pirola, A; D'Aliberti, D; Massimino, L; Criscuolo, L; Pagani, L; Chinello, C; Mastini, C; Fontana, D; Bombelli, S; Meneveri, R; Lovisa, F; Mussolin, L; Janikova, A; Pospíšilová, Š; Turner, S; Inghirami, G; Magni, F; Urso, M; Pagni, F; Ramazzotti, D; Piazza, R; Chiarle, R; Gambacorti-Passerini, C; Mologni, L
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1
2024 Fontana, D; Malighetti, F; Villa, M; Zambon, A; Gambacorti-Passerini, C; Mologni, L
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1
2024 Fontana, D; Malighetti, F; Villa, M; Zambon, A; Gambacorti-Passerini, C; Mologni, L
Characterization of cancer subtypes associated with clinical outcomes by multi-omics integrative clustering
2023 Crippa, V; Malighetti, F; Villa, M; Graudenzi, A; Piazza, R; Mologni, L; Ramazzotti, D
DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients
2023 Malighetti, F; Arosio, G; Manfroni, C; Mauri, M; Villa, M; Manghisi, B; Inzoli, E; Rindone, G; Zambrotta, G; Civettini, I; Guglielmana, V; Ramazzotti, D; Giudici, G; Bombelli, S; Perego, R; Piazza, R; Mologni, L; Gambacorti-Passerini, C
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia
2023 Aroldi, A; Mauri, M; Ramazzotti, D; Villa, M; Malighetti, F; Crippa, V; Cocito, F; Borella, C; Bossi, E; Steidl, C; Scollo, C; Voena, C; Chiarle, R; Mologni, L; Piazza, R; Gambacorti Passerini, C
Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients
2023 Fontana, D; Crespiatico, I; Crippa, V; Malighetti, F; Villa, M; Angaroni, F; De Sano, L; Aroldi, A; Antoniotti, M; Caravagna, G; Piazza, R; Graudenzi, A; Mologni, L; Ramazzotti, D
Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells
2023 Cordani, N; Mologni, L; Piazza, R; Cogliati, V; Pepe, F; Capici, S; DI BELLA, C; Jaconi, M; Cerrito, M; Villa, M; Tettamanti, P; Cavaletti, G; Lavitrano, M; Cazzaniga, M
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells
2023 Cordani, N; Mologni, L; Piazza, R; Tettamanti, P; Cogliati, V; Mauri, M; Villa, M; Malighetti, F; Di Bella, C; Jaconi, M; Cerrito, M; Cavaletti, G; Lavitrano, M; Cazzaniga, M
Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy
2022 Villa, M; Malighetti, F; Sharma, G; Arosio, G; Sala, E; Manfroni, C; Fontana, D; Cordani, N; Meneveri, R; Zambon, A; Piazza, R; Pagni, F; Cortinovis, D; Mologni, L
New advances in liquid biopsy technologies for anaplastic lymphoma kinase (Alk)—positive cancer
2021 Villa, M; Sharma, G; Manfroni, C; Cortinovis, D; Mologni, L